

Analytical Methods

Accepted Manuscript




This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1
2
3
4
5
6 Development and validation of GC-MS/MS method to determinate 21
7
8
9 phthalate leachables in meter dose inhalers.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1

2 **Analysis of 21 phthalate leachables in metered dose inhalers**
3 **by gas chromatography tandem mass spectrometry**

4

Xiaoxia Ye^{a,b}, Juan Ma^a, Yongjian Yang^b, Fang Jin^{a*}

5

^a Shanghai Engineering Research Center of Respiratory Medicine,

6

Shanghai Institute of Pharmaceutical Industry, Shanghai 200437, China.

7

^b Shanghai Institute for Food and Drug Control, Shanghai 201203, China

8

9

10

*Corresponding author:

11

Phone: +086-021-58368001

Fax: +86-21-58368001

12

13

E-mail address: jfsipi@163.com

14

15

16 **ABSTRACT**

17 For the first time, a gas chromatography tandem mass spectrometry
18 method in MRM mode was developed and validated for separation and
19 detection of 21 phthalate leachables in meter dose inhalers (MDI). The
20 optimized method was reliable with high sensitivity and selectivity.
21 Calibration curves were linear with correlation coefficients $R^2 > 0.990$, and
22 the limit of detection (LOD) values for the analytes were in the range of
23 0.1-4.2 ng/ml except for Di(2-methoxyethyl) phthalate (DMEP),
24 Di(2-ethoxyethyl) phthalate (DEEP), Di(2-n-butoxyethyl) phthalate
25 (DBEP), for which LODs were around 10 ng/ml. Recovery ranged
26 between 86.6 and 108.3%, and the RSD values of precision were within
27 7.72%. For the five MDI batches analyzed, 5 out of 21 phthalates were
28 detected in each sample, including Dimethyl phthalate (DMP), Diethyl
29 phthalate (DEP), Diisobutyl phthalate (DIBP), Dibutyl phthalate (DBP)
30 and Di(2-ethylhexyl) phthalate (DEHP), with total phthalate amounts less
31 than 260 ng /canister.

32 **Keywords:** Phthalate, GC-MS/MS, Leachable, Meter dose inhalers

33

1. Introduction

Phthalate esters (PAEs), known as 1,2-Benzenedicarboxylic acid esters, constitute a group of chemical compounds mainly used as plasticizers to improve the performance of plastics. Not forming covalent bonds with the plastics, PAEs can leach from the plastic into the drug formulations. An endocrine disrupting activity of PAEs, linked to estrogenic properties, has been described,¹⁻³ as well as their mutagenic and carcinogenic effects⁴. PAEs such as DEHP (Di(2-ethylhexyl)phthalate) can cause respiratory reactions, and have been identified as important irritants and immunogens of respiratory syndromes including asthma/rhinitis, late respiratory systemic syndrome, pulmonary disease-anemia syndrome.^{5,6} Based on DEHP animal exposure data and incomplete evidence from human epidemiologic studies, the Carcinogen Assessment Group of the US Environmental Protection Agency (EPA) classified plasticizers such as DEHP as “probable human carcinogens”.⁷ For the five phthalates BBP, DBP, DEHP, DEP, DNOP, the U.S. EPA Reference Dose (RfD) for exposure is 0.2, 0.1, 0.02, 0.8 and 0.4 mg/kg/day, respectively.⁸ Therefore, the total daily intake (TDI) of BBP, DBP, DEHP, DEP and DNOP should not exceed 12, 6, 1.2, 48 and 24 mg, respectively, for a 60 kg adult. Due to the potential risks for human health and environment, several PAEs have been included in the priority list of pollutants by different organizations. In Europe, the regulation (EC) NO. 1223/2009⁹ prescribes that some phthalates such as DBP or DEHP should phase out of cosmetics, while others such as diethyl phthalate (DEP) are still used without restrictions in many products. The FDA published a guidance for industry entitled “Limiting the Use of Certain Phthalates as Excipients in CDER-Regulated Products”¹⁰ in October 2012 to restrict the

1
2
3
4 62 use of DBP and DEHP in pharmaceutical products. Following FDA's lead,
5
6 63 the European Medicines Agency (EMA) restricted the use of phthalates in
7
8 64 human medicines in 2013.
9

10 65
11 66 MDI (metered dose inhaler) is a type of drug/device combination
12
13 67 products used in the treatment of a variety of lung diseases, including
14
15 68 asthma, chronic obstructive pulmonary disease (COPD), such as
16
17 69 emphysema or chronic bronchitis and allergic rhinitis, as well as systemic
18
19 70 diseases such as diabetes.¹¹ MDI consists of a solution or suspension
20
21 71 formulation of a drug substance, hydrofluoroalkane (HFA) propellant that
22
23 72 facilitates aerosol dose delivery, surfactant, co-solvents and other
24
25 73 excipients that help to stabilize the formulation. The container closure and
26
27 74 device system includes a metal canister to contain the pressurized
28
29 75 formulation, a valve to meter the dose to patient, elastomeric components
30
31 76 to seal the valve to the canister, and an actuator mouthpiece to facilitate
32
33 77 patient self-dosing. HFA is a mid-polar solvent, with dissolvability as
34
35 78 strong as that of dichloromethane. Due to HFA's high dissolvability, the
36
37 79 organic chemicals, either purposefully added to the device materials (e.g.
38
39 80 polymerization agents, antioxidants, plasticizers) or present in the
40
41 81 materials as by-product of synthesis, may leach from device components
42
43 82 into formulation, and thus be delivered to the patient.
44
45
46

47 83 According to the FDA "Guidance for Industry: Container Closure
48
49 84 Systems for Packaging Human Drugs and Biologics", inhalable aerosols
50
51 85 are used as pharmaceutical products in which the likelihood of packaging
52
53 86 component–dosage form interaction is the highest. Therefore, the amount
54
55 87 of leachables such as phthalate plasticizers in MDI should be limited to
56
57 88 safety range. Therefore, the development of reliable analytical methods
58
59
60

1
2
3
4 89 for PAEs detection is essential in MDI quality control.
5
6
7 90

8
9 91 Although many reports have been published on PAEs determination,
10 most of them focus on plastic materials,^{12,13} water,¹⁴ vegetables,¹⁵
11 cosmetics,¹⁶ soil,¹⁷ and wine.^{18,19} For instrumental analysis, gas
12 chromatography (GC) methods with flame ionization detection¹² or with
13 mass spectrometry detection operating in single ion monitoring (SIM)¹³⁻¹⁹
14 have been reported for PAEs determination. In addition, HPLC coupled to
15 mass spectrometry and UV spectroscopy has been used in PAEs detection.
16
17 95
18 96
19 97
20 98
21 99
22 100
23 101
24 102
25 103
26 104
27 105
28 106
29 107
30 108
31 109
32 110
33 111
34 112
35 113
36 114
37 115
38 116
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

20,21 Most of these assays require various preconcentration techniques, such as liquid-liquid extraction,^{13,17} stir bar sorptive extraction,¹⁵ matrix solid-phase dispersion,¹⁶ and solid-phase extraction.^{12,14,18}

102 The multiple reaction monitoring mode (MRM) based on tandem
103 mass spectrometry (MS/MS) combines high selectivity and sensitivity,
104 and constitutes an excellent analysis tool for trace amounts in a complex
105 matrix, where there are normally high intensities of background signals.
106 The use of tandem quadrupole QqQ enables adequate precursor and
107 product ions selection and allows reducing the chemical noise in
108 chromatograms. In addition, the two steps of mass analysis in MS/MS
109 systems based on QqQ offers the possibility of applying multiple reaction
110 monitoring (MRM). Indeed, GC-MS/MS has been successfully used to
111 determine low levels of leachable components in implantable medical
112 devices.²² To our knowledge, GC-MS/MS in MRM mode has not been
113 reported for detection of PAEs trace amounts.

115 This paper focuses on the simultaneous quantitation of 21 PAEs by
116 GC-MS/MS in MRM mode, covering most of common phthalate

1
2
3
4 117 plasticizers, in meter dose inhalers. To date, no study has been reported
5
6 118 on detection of leachable PAEs in MDI by GC tandem mass spectrometry.
7
8 119

9 120 **2. Experimental**

10 121 *2.1 Reagents*

11 122 The 21 PAEs (chemical names and CAS numbers listed in Table.1)
12 123 and DBP-d4 were all purchased from Dr. Ehrenstorfer GmbH (Germany);
13 124 purity ranged from 99.5 to 100.0%. Analytical-reagent grade acetonitrile
14 125 was provided by MERCK.
15
16
17
18
19
20
21
22
23

24 127 *2.2 Instruments*

25 128 The GC-MS system was composed of an Agilent 7890 gas
26 129 chromatograph and an Agilent 7000A triple quadrupole (QqQ) mass
27 130 spectrometer (MS/MS).
28
29
30
31
32
33

34 132 The GC inlet was operated in splitless mode, held at a temperature
35 133 of 220°C and lined with a single taper deactivated inlet liner. Analytes
36 134 were separated on a 30m DB-5MS (5%-diphenyl;
37 135 95%-dimethylpolysiloxane) capillary column with 0.25 mm internal
38 136 diameter and 0.25 µm film thickness. The initial oven temperature was
39 137 60°C, held for 5 min, increased to 210°C at 10 °C/min, increased to
40 138 250°C at 5 °C /min, increased to 280°C at 10 °C/min and held 6 min
41 139 (total run time 33.8 min). The helium carrier gas in column was
42 140 maintained at a constant flow of 1 mL/min with an injection volume of 1
43 141 µL. The GC-MS/MS interface temperature was maintained at 280 °C.
44
45
46
47
48
49
50
51
52
53
54
55
56

57 143 Mass spectrometric ionization was undertaken in electron-impact
58 144 ionization mode with an EI voltage of 70 eV and a source temperature of
59 145 230°C. The temperature of quadrupole analyzer was maintained at 150°C.
60

1
2
3
4 146 For collision induced dissociation (CID) experiments, ultra high purity
5
6 147 nitrogen gas at 1.5 mL/min and helium quenching gas at 2.25 mL/min
7
8 148 were used. The collision energy was optimized for individual chemicals
9
10 149 to achieve a maximum peak response. The components were detected and
11
12 150 quantified by multiple reaction monitoring (MRM) mode with the gain
13
14 151 set to 30 for all analytes. In order to identify the most suitable transitions
15
16 152 for MRM, analytical standards were initially analyzed in scan mode to
17
18 153 determine suitable precursor ions in MS1 with a scan range of m/z 30 to
19
20 154 m/z M+10 (where M is the mass of the compound of interest).
21
22 155 Fragmentation of precursor ions in the collision cell was assessed by
23
24 156 performing a production scan using the same mass range and scan time.
25
26 157 Product ion intensity was optimized for each transition at different
27
28 158 collision energies. All samples were run with a solvent delay of 3.5 min
29
30 159 and the analytes were separated into 7 discrete time segments for MRM
31
32 160 monitoring with dwell times ranging from 10 to 50 ms, depending on the
33
34 161 time segment, to achieve 5 cycles/s across each peak for optimal
35
36 162 quantification. All ions were monitored at wide resolution (1.2 amu at
37
38 163 half height).
39
40
41 164

42
43 165 The ion transitions monitored for all analytes and collision energies
44
45 166 for the method are presented in Table 1. The Agilent Mass Hunter v.
46
47 167 B.04.01 software was used for data acquisition.
48
49 168

50
51 169 **Table 1** GC-MS/MS method parameters for each analyte.
52
53 170

54 55 171 *2.3 Method validation*

56
57 172 DBP-d4 was used as the internal standard, dissolved and diluted to
58
59 173 1000 ng/mL with acetonitrile to prepare the IS stock solution. PAEs stock
60
174 solutions (200 $\mu\text{g/mL}$) of each PAEs analytes were dissolved in

1
2
3
4 175 acetonitrile and serially diluted to prepare the working standards at 4, 20,
5
6 176 40, 80, 120, 160, and 200 ng/mL, except DMEP, DEEP and DBEP for
7
8 177 which 40, 200, 400, 800, 1200, 1600, and 2000 ng/mL working standards
9
10 178 were prepared.

11
12 179 The limit of detection (LOD) and limit of quantitation (LOQ) were
13
14 180 determined by analysis of 1 μ L of each standard dilution. Precision on
15
16 181 standard solution were assessed at three concentration levels (40 ng/mL,
17
18 182 80 ng/mL, and 200 ng/mL). Accuracy was evaluated with the spiking
19
20 183 recovery experiment. Spiked samples were prepared by adding PAEs
21
22 184 stock solutions to matrix samples at three different concentration (40
23
24 185 ng/mL, 80 ng/mL, and 200 ng/mL).

25 26 27 28 187 *2.4 Samples and analytical procedure*

29
30 188 The metal canister of meter dose inhalers contains the pressurized
31
32 189 formulation. Therefore, the pressure should be released before any assay.
33
34 190 This was done by creating a small hole on the meter valve with an awl to
35
36 191 discharge the propellant slowly, operating with caution to avoid jetting.
37
38 192 When the propellant was completely discharged, MDIs were individually
39
40 193 opened with a tubing cutter, the contents completely transferred into a 5
41
42 194 mL flask, followed by addition of 0.5 mL IS stock solution and
43
44 195 acetonitrile to the mark. The solution was centrifuged for 5 min at 4000
45
46 196 rpm with a glass centrifuge tube, in case of unclear solution.

47
48
49 197
50
51 198 All glassware used was washed with acetone, rinsed with hexane
52
53 199 and dried at 80°C for at least 2 hours, in order to eliminate phthalate
54
55 200 contamination.

56 57 58 59 202 **3. Results and discussion**

60 203 *3.1. GC separation*

1
2
3
4 204 The separation conditions were optimized using a standard mixture
5
6 205 of 21 PAEs at 1 $\mu\text{g/mL}$ with scan mode. DB-1MS and DB-5MS capillary
7
8 206 columns of 30 m \times 0.25 mm \times 0.25 μm were compared and better
9
10 207 separation was achieved with DB-5MS. Therefore the latter was selected
11
12 208 for further experiments. The temperature program was further optimized
13
14 209 to achieve an efficient separation of the 21 PAEs. Fig.1A shows a
15
16 210 chromatogram of a 120 ng/mL standard solution (DMEP, DEEP and
17
18 211 DBEP at 1200 ng/mL). All PAEs except DINP and DIDP were
19
20 212 chromatographically separated on DB-5MS. Both DINP and DIDP are
21
22 213 complex mixtures of isomers, and the chromatographic signal consist of
23
24 214 many peaks. Although a slight co-elution of DINP and DIDP was
25
26 215 observed, DINP and DIDP were also effectively detected in our method,
27
28 216 by monitoring different quantifier transitions, as showed in Fig.1B and
29
30 217 1C. As there are two chiral carbons in the BMPP molecule, BMPP
31
32 218 appears as two incompletely separated isomer peaks in the chromatogram.
33
34 219 Both isomers have almost the same mass fragmentations, and can't be
35
36 220 differentiated by MRM mode, so they were co-detected and quantified.

221

222 After comparison between 220 $^{\circ}\text{C}$ and 280 $^{\circ}\text{C}$, 220 $^{\circ}\text{C}$ was selected as
223 injection temperature, yielding a better injection precision.

224

225 **Fig.1.** GC-MS/MS chromatogram of 120 ng/ml standard solution.

226 A: Total ion chromatogram of mixed standard solution

227 1: DMP, 2: DEP, 3: DIPrP, 4: DAP, 5: DPPrP, 6: DIBP, 7: DBP& DBP-d4, 8:
228 DMEP, 9: DIPP 10: BMPP, 11: DEEP, 12: DPP, 13: BBP, 14: DHP, 15: DBEP, 16:
229 DCHP, 17: DEHP, 18: DPHP, 19: DNOP, 20: DNP, 21: DIDP

230 B: MRM chromatogram of DNP (293 \rightarrow 149)

231 C: MRM chromatogram of DIDP (307 \rightarrow 149)

232

233 3.2 Optimization of MS parameters

234 In order to enhance the sensitivity of detection, mass spectrometry
235 parameters were optimized. Careful attention was paid to the selection of

1
2
3
4 236 suitable MRM transitions to produce product ions of high intensity and
5
6 237 minimal background noise. Analytical standards were initially analyzed
7
8 238 in scan mode, fragmentation with higher m/z and response was picked out
9
10 239 as precursor ion. Then the fragmentation of precursor ions in the collision
11
12 240 cell was assessed by performing a production scan, fragmentation with
13
14 241 higher m/z and response was picked out as product ion. Compared by the
15
16 242 response and background noise, quantitation transition and qualification
17
18 243 transition with different precursor may be selected. Take DIPP for
19
20 244 example, the precursor ion of the quantitation and qualification transition
21
22 245 were 237 and 149 respectively. Response result in different collision
23
24 246 energy may vary to a different degree. Therefore, product ion formation
25
26 247 was optimized at variable collision energies (between 5 and 25ev) once
27
28 248 the transitions were selected, to achieve high sensitivity. The response of
29
30 249 transition 149→121 of DIPP at different collision energy levels is shown
31
32 250 in Fig.2. The highest response was achieved at 15ev. Dwell times were
33
34 251 adjusted to provide 5 cycle/s for sufficient peak scan. As the response of
35
36 252 the qualifier transition 293→71 of DINP is low, another qualifier
37
38 253 transition 293→167 was selected at the same time, in order to improve
39
40 254 specificity. The same is valid for DIDP.
41
42
43
44

45 **Fig.2** Effect of collision energy (ev) on the transition 149→121 of DIPP.
46
47

48 258 3.3 Method validation

49
50
51 259 The optimized method was validated for linearity, detection limits,
52
53 260 quantification limits, precision and accuracy. Calibration curves were
54
55 261 constructed for each analyte, plotting (peak area of analyte quantifier
56
57 262 transition)/(peak area of IS transition) versus concentration. The
58
59 263 calibration curves were linear for all the standards with regression values
60
264 (R^2) ranging from 0.9902 to 0.9985 (Table.2).

1
2
3
4 265 Although all possible precautions were taken, the presence of trace
5
6 266 phthalates in solvent could not be avoided. The limit of detection (LOD)
7
8 267 and quantification (LOQ) were calculated based on a signal-to-noise ratio
9
10 268 of 3 and 10 (Table 2), respectively, excluding DEP, DIBP, DBP, and
11
12 269 DEHP, detected in the blank solvent (acetonitrile). LODs and LOQs for
13
14 270 these compounds were estimated as the average amount of analyte giving
15
16 271 a response that is the signal plus 3 or 10 times the standard deviation,
17
18 272 respectively. LODs of the PAEs studied were around 1.0 ng/mL, except
19
20 273 for DMEP, DEEP, DBEP, DINP and DIDP. The respective values are
21
22 274 listed in Table 2. Due to the high selectivity of MRM mode, the noise in
23
24 275 the MRM chromatogram (307→149) of DINP tends to be zero. Therefore,
25
26 276 detection was still possible even at level as low as to 3.9 ng/mL, despite
27
28 277 the relatively low height of DINP peak (Fig.1). The same is valid for
29
30 278 DIDP. LOQs ranged from 0.4 to 8.3 ng/mL, with the exception of DMEP,
31
32 279 DEEP and DBEP (36.5~41.2 ng/mL).

33
34 280 Precision on standard solution was studied within day (n=6) and
35
36 281 between days (n=6) at low, medium, and high levels (40, 80, 160 ng/mL).
37
38 282 Intraday precision expressed as the relative standard deviations (RSDs) for
39
40 283 all analytes were listed in Table 2, varied from 1.52 to 7.72%. Interday
41
42 284 RSDs values range from 1.64 to 8.45%.

43
44
45 285
46
47 286 **Table 2** Characteristics of the optimized method.
48
49 287

50
51 288 The matrix effects of the 21 PAEs were estimated by comparing the
52
53 289 corresponding response factors for the spiked sample to those of pure
54
55 290 standards at two levels (40 ng/mL and 160 ng/mL). Matrix effects
56
57 291 between 89.9 to 110.3% were observed, suggesting the minor matrix
58
59 292 effects at acceptable levels. Therefore, the standard in acetonitrile was
60
293 used to calculate the linearity and sample assay.

1
2
3
4 294 Method accuracy were evaluated with spiking experiments at three
5
6 295 levels (40, 80, 160 ng/mL, n=3) (Table.2). As shown in Table 2, recovery
7
8 296 calculated by calibration curves ranged from 86.6 to 108.3%.
9

10 297

11 298 *3.4 Analysis of samples*

12
13
14 299 The developed method was applied to five meter dose inhaler
15
16 300 batches. Three samples were prepared and analyzed respectively for each
17
18 301 batch. The analytes were identified by comparing the retention time and
19
20 302 the response ratio of qualifier ion to target ion in samples and standard
21
22 303 solutions. Five PAEs were found in all meter dose inhalers, including
23
24 304 DMP, DEP, DIBP, DBP and DEHP, and the others were not detected in
25
26 305 the analyzed samples. The results are summarized in Table 3. The total
27
28 306 PAEs amounts ranged from 174.4 to 252.5 ng/canister for the five MDI.
29
30 307 There are 200 doses in one canister, and a patient may administer up to 4
31
32 308 doses per day. Accordingly, the patient would inhale 3-5 ng of PAEs with
33
34 309 the drug daily, far less than the allowed intake for the most dangerous
35
36 310 PAEs: DEHP, 0.12 mg/day. DEHP amounts range from 41. 8 to 135.2
37
38 311 ng/canister, accounting for 24~54% of the total PAEs. These data suggest
39
40 312 that DEHP is the main phthalate plasticizer in meter valve materials. Due
41
42 313 to the special inhalation route, in which the chemical may directly enter
43
44 314 into the blood system, PAEs leachable in MDI should be controlled
45
46 315 within the safe range. Although the amounts of PAEs in MDI are far less
47
48 316 than reference doses proposed by the U.S. EPA, MDI developers and
49
50 317 manufacturers should still pay close attention to leachable PAEs. Also,
51
52 318 this research field should be intensified to ensure the safety of MDI.
53
54
55
56

57 319

58 320 **Table 3** Contents (ng/canister) of MDI products (n=3).

59 321

60 322 **4. Conclusion**

1
2
3
4 323 This paper describes the development and validation of a reliable
5
6 324 GC-MS/MS method for the determination of PAEs leachable. 21 PAEs
7
8 325 could be simultaneously analyzed in this optimized method. The method
9
10 326 was applied to five batches of MDI, and five phthalate plasticizers (DMP,
11
12 327 DEP, DIBP, DBP and DEHP) were found in MDI products as leachable.
13
14 328 MDI developers and manufacturers should pay close attention to the
15
16 329 PAEs leachable in MDI products to ensure quality and safety of their
17
18 330 products.

331

332 **References**

- 333 [1] R. Benson, Hazard to the developing male reproductive system from cumulative exposure to
334 phthalate esters-dibutyl phthalate, diisobutyl phthalate, butylbenzyl phthalate, diethylhexyl
335 phthalate, dipentyl phthalate, and diisononyl phthalate. *Regul. Toxicol. Pharm.*, 2009,53, 90-101.
- 336 [2] T. Stroheker, N. Cabaton, G. Nourdin, J.F Regnier, J.C. Lhuguenot, M.C. Chagnon,
337 Evaluation of anti-androgenic activity of di-(2-ethylhexyl)phthalate Toxicology,
338 2005,208,115-121.
- 339 [3] M. Matsumoto, M. Hirata-Koizumi, M. Ema, Potential adverse effects of phthalic acid esters
340 on human health: A review of recent studies on reproduction. *Regul Toxicol Pharm.*,
341 2008,50 , 37-49.
- 342 [4] H. JW, Carcinogenicity of general-purpose phthalates:structure-activity relationships *Drug*
343 *Metab Rev.* 1989,21,55.
- 344 [5] S.H. Sandra , R Brenda shaw, A. Wu , The clinical effects of plasticizers, antioxidants, and
345 other contaminants in medical polyvinylchloride tubing during respiratory and
346 non-respiratory exposure.*Clin.Chim.Acta*, 2001,304, 1-8.
- 347 [6] A.R. Bardana, Occupational asthma secondary to low molecular weight agents used in the
348 plastic and resin industries. *Eur. J. Resp. Dis*, 1983,64 , 241-251.
- 349 [7] C.O Schulz, Assessing human health risks from exposure to di(2-ethylhexyl) phthalate
350 (DEHP) and related phthalates. *Drug. Metab. Rev.*, 1989,21 , 111-120.
- 351 [8] http://www.epa.gov/teach/chem_summ/phthalates_summary.pdf. Phthalate.
- 352 [9] Regulation (EC) No. 1223/2009 of the European Parliament and of the Council of 30
353 November 2009 on Cosmetic Products (recast), *Off. J. Eur. Union* L342 (2009)59.
- 354 [10] [http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm](http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm330792.htm)
355 [330792.htm](http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm330792.htm) Guidance for Industry Limiting the Use of Certain Phthalates as Excipients in
356 CDER-Regulated Products(2012).
- 357 [11] S. Newman, P. Anderson, P.Byron, R. Dalby, J.Peart, Respiratory Drug Delivery Essential

- 1
2
3 358 Theory&Practice.2009. ISBN 978-7-122-10756-5
- 4
5 359 [12] X. Li, Z. Zeng, Y. Chen, Y. Xu, Determination of phthalate acid esters plasticizers in plastic
6
7 360 by ultrasonic solvent extraction combined with solid-phase microextraction using
8
9 361 calix[4]arene
10
11 362 fiber. *Talanta*,2004, 63, 1013-1019.
- 12
13 363 [13] T. Niino, T. Ishibashi, T. Itho, S. Sakai, H. Ishiwata, T. Yamada, S. Onodera, Simultaneous
14
15 364 determination of phthalate di- and monoesters in poly(vinylchloride) products and human
16
17 365 saliva by gas chromatography mass spectrometry.*J. Chromatogr. B.* 2002,780, 35-44.
- 18
19 366 [14] Y.B Luo, B.F. Yuan, Y.Q. Feng, Fast microextraction of phthalate acid esters from beverage,
20
21 367 environmental water and perfume samples by magnetic multi-walled carbon nanotubes.
22
23 368 *Talanta*. 2012, 123-131.
- 24
25 369 [15] J. I.Cacho, N.Campillo,P.Viñas, M.Hernandez-córdoba, Determination of alkylphenols and
26
27 370 phthalate esters in vegetables and migration studies from their packages by means of stir bar
28
29 371 sorptive extraction coupled to gas chromatography mass spectrometry.*J. Chromatogr. A.*
30
31 372 2012, 1241,21-27.
- 32
33 373 [16] M. Llompарт, M. Celeiro, J. Pablo Lamas, L. Sanchez-Prado, M. Lores, C. Garcia-Jares,
34
35 374 Analysis of plasticizers and synthetic musks in cosmetic and personal care products by
36
37 375 matrix solid-phase dispersion gas chromatography mass spectrometry. *J. Chromatogr. A.*
38
39 376 2013,1293, 10-19.
- 40
41 377 [17] S. Kong, Y. Ji, L. Liu, L. Chen, X. Zhao, J. Wang, Z. Bai, Z. Sun, Diversities of phthalate
42
43 378 esters in suburban agricultural soils and wasteland soil appeared with urbanization in China.
44
45 379 *Environ. Pollut.* 2012, 170, 161-168.
- 46
47 380 [18] M. Del Carlo, A. Pepe, G. Sacchetti, D. Compagnone, D. astrocola, A. Cichelli,
48
49 381 Determination of phthalate esters in wine using solid-phase extraction and gas
50
51 382 chromatography mass spectrometry. *Food. Chem.* 2008,111, 771-777.
- 52
53 383 [19] G. Cinelli, P. Avino, I. Notardonato, A. Centola, M.V. Russo, Rapid analysis of six
54
55 384 phthalate esters in wine by ultrasound-vortex-assisted dispersive liquid- liquid
56
57 385 micro-extraction coupled with gas chromatography-flame ionization detector or gas
58
59 386 chromatography mass on trap mass spectrometry. *Analy. Chim. Acta.* 2013, 769, 72-78.
- 60
387 [20] A. Mtibe, T.A.M. Msagati, A.K. Mishra, B.B. Mamba, Determination of phthalate ester
388
389 388 plasticizers in the aquatic environment using hollow fibre supported liquid membranes.
390
391 389 *Phys. Chem.Earth. Parts A/B/C* 2012,50-52,239-242.
- 392
393 [21] L. Lu, Y. Hashi, Z.H. Wang, Y. Ma, J.M. Lin, Determination of phthalate esters in
394
395 390 physiological saline solution by monolithic silica spin column extraction method. *J.Pharma.*
391
392 391 *Analy.* 2011,1, 92-99.
- 393
394 [22] Barbara L.A, Askim F.S, Venkat Narayan, Xiande Wang, Lori. A, Gyorgy Vas. Stir bar
395
396 393 sorptive extraction combined with GC-MS/MS for determination of low level leachable
397
398 394 components from implantable medical devices. *J.Pharm. Biomed, Anal,* 2013,74,162-170.

396 **Table 1:** GC-MS/MS method parameters for each analyte

Key	Compound name	CAS	Retention Time(min)	Quantitation Transition(ev)*	Qualitation Transition(ev)*
DMP	Dimethyl phthalate	131-11-3	11.7	163→133 (10)	163→135 (25)
DEP	Diethyl phthalate	84-66-2	12.6	149→121 (15)	177→149 (25)
DIPrP	Diisopropyl phthalate	605-45-8	13.0	149→121 (15)	209→149 (5)
DAP	Diallyl phthalate	131-17-9	13.6	132→104 (15)	189→41 (25)
DPrP	Dipropyl phthalate	131-16-8	13.8	149→121 (15)	209→149 (5)
DIBP	Diisobutyl phthalate	84-69-5	14.5	149→121 (15)	223→149 (5)
DBP	Dibutyl phthalate	84-74-2	15.2	149→121 (15)	223→149 (5)
DBP-d4	Dibutyl phthalate-d4	93952-11-5	15.2	227→153 (15)	209→153 (15)
DMEP	Di(2-methoxyethyl) phthalate	117-82-8	15.6	149→121 (15)	207→59 (5)
DIPP	Diisopentyl phthalate	605-50-5	16.3	149→121 (15)	237→149 (5)
BMPP	Bis(4-methyl-2-pentyl) phthalate	146-50-9	16.4	167→149 (15)	251→167 (10)
DEEP	Di(2-ethoxyethyl) phthalate	605-54-9	16.7	193→149 (15)	149→121 (15)
DPP	Dipentyl phthalate	131-18-0	17.1	149→121 (15)	237→149 (5)
DHP	Dihexyl phthalate	84-75-3	19.3	149→121 (15)	251→149 (20)
BBP	Benzyl butyl phthalate	85-68-7	19.4	149→121 (15)	206→149 (5)
DBEP	Di(2-n-butoxyethyl) phthalate	117-83-9	20.9	149→121 (15)	193→121 (5)
DCHP	Dicyclohexyl phthalate	84-61-7	21.5	149→121 (10)	249→149 (25)
DEHP	Di(2-ethylhexyl)phthalate	117-81-7	21.7	149→121 (10)	279→149 (20)
DPHP	Diphenyl phthalate	84-62-8	21.8	225→77 (25)	225→197 (10)
DNOP	Dinooctyl phthalate	117-84-0	23.6	149→121 (15)	279→149 (20)
DINP	Diisononyl phthalate	28553-12-0	24.1	293→149 (15)	293→71 (10) 293→167 (5)
DIDP	Diisodecyl-o-phthalate	26761-40-0	26.1	307→149(15)	307→71 (10) 307→167 (5)

397 *Listed in the brackets were the collision energy.

398 **Table 2:** Characteristics of the optimized method.


compound	R ²	LOD ng/mL	Intraday Precision, RSD(%) (n=6)			Recovery Average(%) ± SD(n=3)		
			40 ng/mL ^a	80 ng/mL ^b	160 ng/mL ^c	40 ng/mL ^a	80 ng/mL ^b	160 ng/mL ^c
DMP	0.9913	0.2	4.08	3.86	4.24	92.1 ± 2.13	102.3 ± 0.45	90.7 ± 3.78
DEP	0.9959	1.0	4.34	2.20	4.66	98.3 ± 2.22	98.9 ± 0.64	93.4 ± 3.33
DIPrP	0.9973	0.2	3.28	1.52	4.08	101.4 ± 4.14	100.5 ± 1.03	99.4 ± 1.52
DAP	0.9951	1.1	1.83	1.75	4.37	102.9 ± 2.73	98.3 ± 1.23	100.2 ± 2.56
DPrP	0.9919	0.4	2.05	1.40	4.22	99.9 ± 4.44	101.3 ± 1.44	97.7 ± 1.32
DIBP	0.9929	0.2	1.53	2.01	3.85	105.4 ± 2.04	98.7 ± 1.43	101.8 ± 1.67
DBP	0.9985	0.2	2.15	2.65	3.88	107.5 ± 3.57	100.2 ± 2.52	107.6 ± 1.68
DMEP	0.9902	10.3	4.18	6.25	3.10	103.0 ± 4.06	96.8 ± 1.78	108.3 ± 1.64
DIPP	0.9983	1.0	3.47	3.49	3.49	92.7 ± 1.54	96.8 ± 2.90	90.9 ± 1.79
BMPP	0.9985	0.2	2.08	2.09	3.60	89.2 ± 2.89	95.5 ± 2.01	94.6 ± 1.56
DEEP	0.9968	10.1	3.45	6.28	4.32	93.1 ± 2.67	98.6 ± 2.47	101.4 ± 1.02
DPP	0.9973	0.4	2.66	4.23	4.55	88.8 ± 2.73	101.7 ± 1.64	100.6 ± 1.89
DHP	0.9967	0.4	3.35	4.50	4.27	87.5 ± 2.44	93.3 ± 2.33	88.1 ± 1.02
BBP	0.9979	1.0	3.17	4.25	4.78	88.5 ± 3.43	92.7 ± 3.32	86.6 ± 2.43
DBEP	0.9956	9.1	4.85	5.90	4.90	89.9 ± 3.87	99.6 ± 1.52	101.8 ± 1.89
DCHP	0.9969	1.0	3.16	4.42	4.38	89.0 ± 3.01	87.1 ± 5.42	92.2 ± 2.43
DEHP	0.9959	1.1	3.00	5.81	3.37	102.2 ± 2.89	102.8 ± 6.44	91.7 ± 3.22
DPHP	0.9955	0.1	4.78	7.11	4.76	92.1 ± 4.53	95.5 ± 1.68	97.1 ± 4.51
DNOP	0.9977	1.0	4.86	7.72	4.39	97.7 ± 4.21	96.3 ± 0.40	89.8 ± 5.32
DINP	0.9956	3.9	7.44	5.81	5.75	99.5 ± 6.23	106.2 ± 1.53	94.1 ± 5.21
DIDP	0.9920	4.2	6.82	7.14	7.01	104.4 ± 4.02	94.7 ± 1.71	102.6 ± 5.73

399 **Table 3:** Contents (ng/canister) of MDI products (n=3).

compound	MDI 1 mean \pm SD	MDI 2 Mean \pm SD	MDI 3 Mean \pm SD	MDI 4 Mean \pm SD	MDI 5 Mean \pm SD
DMP	23.5 \pm 1.21	29.0 \pm 4.01	60.2 \pm 6.28	17.3 \pm 1.03	17.4 \pm 0.54
DEP	21.9 \pm 1.82	20.2 \pm 0.74	22.1 \pm 2.31	26.5 \pm 8.32	22.6 \pm 3.63
DIPrP	ND	ND	ND	ND	ND
DAP	ND	ND	ND	ND	ND
DPrP	ND	ND	ND	ND	ND
DIBP	34.9 \pm 7.90	59.6 \pm 6.68	25.3 \pm 7.87	27.8 \pm 3.82	64.4 \pm 7.23
DBP	37.0 \pm 6.93	33.3 \pm 6.76	43.1 \pm 6.82	42.4 \pm 0.54	28.4 \pm 5.13
DMEP	ND	ND	ND	ND	ND
DIPP	ND	ND	ND	ND	ND
BMPP	ND	ND	ND	ND	ND
DEEP	ND	ND	ND	ND	ND
DPP	ND	ND	ND	ND	ND
DHP	ND	ND	ND	ND	ND
BBP	ND	ND	ND	ND	ND
DBEP	ND	ND	ND	ND	ND
DCHP	ND	ND	ND	ND	ND
DEHP	135.2 \pm 7.56	82.5 \pm 4.04	87.5 \pm 2.67	62.5 \pm 7.88	41.8 \pm 6.77
DPHP	ND	ND	ND	ND	ND
DNOP	ND	ND	ND	ND	ND
DINP	ND	ND	ND	ND	ND
DIDP	ND	ND	ND	ND	ND
SUM	252.5 \pm 10.53	224.4 \pm 13.38	238.2 \pm 19.48	176.3 \pm 4.11	174.4 \pm 14.13

400 ND: not detected

401




402

A


403

404



405

B



C

406

407

408 **Fig.1.** GC-MS/MS chromatogram of 120 ng/ml standard solution.

409 A: Total ion chromatogram of mixed standard solution

410 1: DMP, 2: DEP, 3: DIPrP, 4: DAP, 5: DPrP, 6: DIBP, 7: DBP& DBP-d4, 8: DMEP, 9: DIPP

411 10: BMPP, 11: DEEP, 12: DPP, 13: BBP, 14: DHP, 15: DBEP, 16: DCHP, 17: DEHP, 18: DPHP,

412 19: DNOP, 20: DNP, 21: DIDP

413 B: MRM chromatogram of DNP (293 → 149)

414 C: MRM chromatogram of DIDP (307 → 149)

415




Fig.2. Effect of collision energy on the transition 149 \rightarrow 121 of DIPP.